Eftrenonacog Alfa

Summary

Eftrenonacog Alfa (CHEMBL4594598) is an approved protein; indicated across 2 conditions including hemophilia b and hemophilia a.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• Indications: 2 conditions
• Clinical trials: 8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4594598
Name	Eftrenonacog Alfa
Type	Protein
Max phase	4

Also known as: Alprolix, BIIB-029, Eftrenonacog alfa, Rfixfc, EFTRENONACOG ALFA

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hemophilia B	4	MONDO:0010604	MONDO:0010604
hemophilia A	0	MONDO:0010602	MONDO:0018660

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
Not specified	4
PHASE3	3
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01425723	PHASE3	COMPLETED	Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B
NCT01440946	PHASE3	COMPLETED	Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B
NCT02234310	PHASE3	COMPLETED	Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B
NCT00716716	PHASE1	COMPLETED	Phase I/IIa Study of FIXFc in Hemophilia B Patients
NCT02392156	Not specified	TERMINATED	Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes
NCT03055611	Not specified	COMPLETED	A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B
NCT03655340	Not specified	COMPLETED	A Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B in France
NCT03901755	Not specified	COMPLETED	An International Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).